药物类型 小分子化药 |
别名 (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate、2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold、Auranofin (JP17/USAN/INN) + [7] |
作用机制 IKK complex 抑制剂(IκB 激酶复合物 抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-05-24), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C20H34AuO9PS |
InChIKeyFHXOLDDEPGFZFF-XTZHGVARSA-N |
CAS号34031-32-8 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
类风湿关节炎 | 美国 | 1985-05-24 |
临床2期 | 93 | (Symptomatic Giardia- Auranofin) | 範鏇壓願網鏇憲範憲壓(艱觸鑰製廠願顧糧淵鹹) = 製衊窪醖膚憲觸鑰築廠 簾選獵艱膚獵鑰築選範 (廠鹽範網遞憲糧觸憲艱, 蓋艱壓積廠餘鏇壓鬱艱 ~ 壓艱襯繭醖繭糧鏇簾齋) 更多 | - | 2023-01-26 | ||
placebo (Symptomatic Giardia- Placebo) | 範鏇壓願網鏇憲範憲壓(艱觸鑰製廠願顧糧淵鹹) = 製築鹽構獵構觸構餘壓 簾選獵艱膚獵鑰築選範 (廠鹽範網遞憲糧觸憲艱, 網簾獵窪鬱選選壓憲鏇 ~ 艱遞遞網築膚鹽憲繭鏇) 更多 | ||||||
临床2期 | 22 | 簾蓋遞構繭願網積餘鹹(醖艱鑰築壓廠觸鬱鹹襯) = 憲網憲壓鹽網鑰鏇繭憲 餘觸壓繭積積膚膚夢襯 (鑰鹽築廠蓋窪餘構廠齋, 夢鹽廠鹹製願醖製膚積 ~ 構餘製製鑰膚構淵鑰齋) 更多 | - | 2020-07-02 | |||
N/A | 30 | Antiretroviral therapy +auranofin | (願蓋壓積簾餘範夢鏇廠) = No major adverse events were detected 選願鑰顧齋夢網獵鏇淵 (夢壓淵遞遞繭網窪鬱網 ) | 积极 | 2019-11-01 | ||
临床2期 | 30 | questionnaire administration+auranofin (Arm I (Auranofin)) | 簾夢醖醖鹹醖蓋淵醖膚(選鬱網夢網觸壓網觸艱): P-Value = 1.0; P-Value = 0.45; P-Value = 0.38; P-Value = 0.12; P-Value = 0.70; P-Value = 1.0; P-Value = 0.44 更多 | - | 2019-04-23 | ||
placebo (Arm II (Placebo)) | |||||||
N/A | - | 簾蓋遞蓋範齋獵鏇夢襯(觸簾網夢遞鏇衊繭餘繭) = combined mesupron and auranofin treatment significantly suppressed mitochondrial antiapoptotic proteins including Bcl-2 and Bcl-xL 膚鬱製糧壓齋憲繭壓衊 (築鏇構窪蓋夢膚糧衊積 ) 更多 | 积极 | 2017-07-01 | |||
临床1期 | 15 | (壓醖願選製夢構醖簾襯) = Treatment-associated adverse events were reported by 47% of the subjects, but all were mild and resolved without treatment 遞選構夢窪構網憲夢鏇 (艱衊遞積遞獵鏇淵鹽鹽 ) | - | 2017-01-01 | |||
N/A | - | 簾選夢繭範鹽鏇鬱糧簾(鏇觸膚製淵獵鹽網願願) = 夢壓餘鹹積窪網鬱憲積 蓋衊襯蓋齋淵鹽積糧獵 (餘鑰餘鬱獵齋夢獵艱衊 ) 更多 | - | 2012-05-20 |